Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Medical System Holdings ( (HK:0867) ) has shared an update.
China Medical System Holdings Limited announced that its New Drug Application for Y-3 for Injection, a Class 1 innovative drug for treating acute ischemic stroke, has been accepted by China’s National Medical Products Administration. This drug, noted as the world’s first brain cytoprotectant targeting PSD-95-nNOS and MPO, shows promise in improving treatment outcomes for stroke patients and potentially preventing post-stroke depression and anxiety. The Phase III clinical trial in China demonstrated significant clinical benefits and a favorable safety profile, indicating broad market prospects given the high incidence of stroke in China.
The most recent analyst rating on (HK:0867) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings Limited is a pharmaceutical company focused on innovative drug development and research. The company operates in the healthcare industry, with a market focus on providing advanced treatments for medical conditions, particularly in China.
Average Trading Volume: 5,561,601
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.15B
For an in-depth examination of 0867 stock, go to TipRanks’ Overview page.